stockrow
Saturday 7 November 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024.
- Revenue
- −7.98%
- EPS
- −43.8%
- Free cash flow
- −141.6%
Quarter to March 2026, against a year earlier
46.43
0.85
+1.86%
Follow ANAB
Alert me
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.45 | 3.34 | 3.95 | 4.55 | |
P/FCF ratio |
0.00 | 0.00 | 47.27 | 239.93 | |
P/Operating CF |
(10.57) | (20.71) | 9.46 | (40.81) | |
P/B ratio |
0.00 | 0.00 | 24.91 | 82.99 | |
Price to Tangible BV |
0.00 | 0.00 | 24.91 | 82.99 | |
EV/Sales |
1.31 | 1.89 | 2.63 | 3.33 | |
EV/EBITDA |
0.00 | 0.00 | 13.55 | 19.27 | |
EV/Operating CF |
(1.27) | (2.21) | 31.36 | 172.80 | |
EV/FCF |
(1.26) | (2.20) | 31.50 | 175.50 | |
Quick Ratio |
8.08 | 8.52 | 8.94 | 7.49 | |
Current Ratio |
8.22 | 8.68 | 9.07 | 7.58 | |
Net Debt/EBITDA |
9.78 | (7.28) | (4.64) | 8.42 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.32 | 0.40 | 0.55 | 0.62 | |
Operating CF/Net income |
1.04 | (1.81) | 1.98 | 0.49 | |
Capex/Depreciation |
0.04 | 0.02 | 0.00 | (0.03) | |
Research and Development Expense of Revenue |
169.90% | 41.15% | 23.61% | 133.01% | |
Selling, General and Administrative Expense of Revenue |
47.65% | 13.38% | 14.59% | 102.53% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
41.50% | 12.00% | 7.86% | 55.63% | |
Graham Net Nets |
(0.21) | (0.09) | 0.02 | 0.00 | |
Graham Number |
12.51 | 8.16 | 0.00 | 0.00 | |
Earnings Yield |
(30.35%) | (13.75%) | (0.90%) | (2.31%) | |
Free Cash Flow Yield |
(30.12%) | (25.64%) | 2.12% | 0.42% | |
Revenue per Share |
0.77 | 2.74 | 3.76 | 0.89 | |
Operating CF per Share |
(1.40) | (0.98) | 3.41 | (0.90) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.40) | (0.98) | 3.41 | (0.90) | |
Cash per Share |
9.22 | 8.94 | 10.84 | 9.98 | |
Shareholders Equity per Share |
(1.55) | (1.06) | 1.29 | 0.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.55) | (1.06) | 1.29 | 0.44 | |
Free Cash Flow |
(40.28) | (27.37) | 98.00 | (25.94) | |
Working Capital |
256.38 | 292.55 | 311.63 | 274.41 | |
Capital Expenditures |
(0.04) | (0.01) | 0.00 | (0.02) | |
Net Current Asset Value |
(88.08) | (51.86) | 23.07 | (0.83) | |
EV/EBIT |
0.00 | 0.00 | 12.90 | 18.97 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 19.35 | 25.93 | |
| Other line items | |||||
Average Receivables |
15.21 | 43.94 | 37.31 | 21.82 | |
Average Payables |
4.11 | 3.24 | 3.94 | 6.82 | |
Average Assets |
381.31 | 423.26 | 424.11 | 375.87 | |
Average Common Equity |
(17.43) | 27.48 | 54.04 | 23.38 |
Columns are period end dates